Breast Cancer and Postmenopausal Hormone Therapy

Less HT use parallels recent declines in breast cancer incidence.

The decline in breast cancer incidence that occurred during this decade has been attributed to less use of postmenopausal hormone therapy (HT; JW Oncol Hematol May 14 2007). However, prior investigations of this association have been limited by lack of data on adherence to mammography screening, risk factors for breast cancer, and HT types and doses. To further assess the influence of postmenopausal HT on risk for breast cancer, investigators analyzed results of the Women’s Health Initiative (WHI) study (JW Womens Health Aug 7 2002), a randomized clinical trial involving more than 15,000 postmenopausal women without breast cancer who received either placebo or conjugated estrogen (0.625 mg daily) plus medroxyprogesterone acetate (2.5 mg dai…

Reviewing Authors

Abenaa M. Brewster, MD, MHS

Henry Mark Kuerer, MD, PhD, FACS

Disclosures

Speaker's BureauPhysicians’ Education Resource, LLC

RoyaltiesMcGraw-Hill Professional; UpToDate, Inc.

Editorial BoardsAnnals of Surgical Oncology

Leadership Positions in Professional SocietiesAmerican Society of Breast Surgeons (Chair, Publications Committee)